Xin Zhao

Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Preliminary results of GALAHAD.

H. Scher, D. George, E. Yu, 2019, Journal of Clinical Oncology.

Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial.

H. Scher, D. Danila, O. Ståhl, 2022, The Lancet. Oncology.

A bibliometric and visualized research on global trends of immune checkpoint inhibitors related complications in melanoma, 2011–2021

Yanlong Shi, Jiachao Xiong, Rong Guo, 2023, Frontiers in Endocrinology.

Clinical and genomic characterization of Chinese patients with functional high-risk multiple myeloma: A real-world validation study

T. Zhou, L. Bao, B. Chu, 2023, Frontiers in Oncology.

Vitamin D deficiency linked to abnormal bone and lipid metabolism predicts high-risk multiple myeloma with poorer prognosis

L. Bao, B. Chu, Menghe Wang, 2023, Frontiers in Endocrinology.

CTNI-30. LOGGIC/FIREFLY-2: A PHASE 3, RANDOMIZED TRIAL OF TOVORAFENIB VS. CHEMOTHERAPY IN PEDIATRIC PATIENTS WITH NEWLY DIAGNOSED LOW-GRADE GLIOMA HARBORING AN ACTIVATING RAF ALTERATION

David C. Jones, O. Witt, D. Hargrave, 2022, Neuro-Oncology.

A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641)

E. Small, D. Rathkopf, D. Olmos, 2019, Annals of Oncology.